GRI
What one share of Gri Bio holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic and autoimmune disorders.
Gri Bio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$11.55 |
|---|---|
| Cash and investments | $5.01 |
| Book value | $4.70 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $0.67 | −$32.10 | $0.01 | −$24.69 | — | −$9.68 |
| 2021 | $0.00 | −$42.67 | $0.00 | −$38.12 | — | −$21.35 |
| 2022 | — | −$24.94 | $0.02 | −$8.43 | — | −$11.38 |
| 2025 | — | −$121.80 | $0.03 | −$103.80 | — | $12.07 |